BenevolentAI Platform
Next generation AI platform for life science intelligence and drug discovery
Platform · Cloud SaaSCompany source
Company profile
About BenevolentAI
BenevolentAI is a drug discovery company that uses AI and machine learning to accelerate the discovery and development of new medicines for complex diseases.
Company description BenevolentAI official website
Mission. We build technology in the service of science.
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Work at BenevolentAI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Pharma
- R&D executives
- Scientists
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsLuxembourg
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Artificial intelligence in precision medicine: transforming disease subtyping, medical imaging, and pharmacogenomics.Emerging topics in life sciences · Aug 20, 2025
Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of Glioblastoma.Journal of medicinal chemistry · May 8, 2025
Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.Molecular cancer therapeutics · Apr 2, 2025
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Feb 20, 2025
EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma.Neuro-oncology · Feb 10, 2025
Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for In Vivo Pharmacological Studies.Journal of medicinal chemistry · Dec 12, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Joerg Moeller, M.D.
CEO and Executive Director
James Hunter
Chief Financial Officer | Scaling high-growth, AIM-listed, VC & PE backed businesses | Fund-raising, M&A, IPO, finance transformation and Exit | Lifesciences, Healthcare, Energy Transition & Technology
Raquel Schnitzler
Workplace Designer / Facilities Manager
06 · Company updates
Updates from BenevolentAI
Recent articles published on BenevolentAI's official website.
Video20 Apr 2023BenevolentAI’s approach to AI-enabled drug discoveryRead more
Read on BenevolentAIBlog27 Apr 2023BenevolentAI’s CSO, Anne Phelan, recognised for her contributions to innovation in drug developmentRead more
Read on BenevolentAIBlog01 Jul 2024CSO, Anne Phelan talks to Emerj about the challenges of drug discovery and how AI can be used to tackle thisRead more
Read on BenevolentAIVideo11 Jan 2024Dr Francois Nader • 42nd Annual J.P. Morgan Healthcare ConferenceRead more
Read on BenevolentAIVideo23 Oct 2024Keynote Panel: The benefits of AI within drug discoveryRead more
Read on BenevolentAI07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
The $8.9 Billion Question: Why AI Drug Discovery Still Has Nothing on Pharmacy Shelves
Three years of sliding approval timelines expose a critical gap between artificial intelligence's preclinical promise and the regulatory infrastructure needed to bring AI-discovered medicines to patients.
Drug Discovery & Research · Aug 10, 2026
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
Drug Discovery & Research · Jun 26, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.